SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cyclo Therapeutics, Inc. – ‘10-Q’ for 6/30/22

On:  Monday, 8/15/22, at 4:06pm ET   ·   For:  6/30/22   ·   Accession #:  1437749-22-20532   ·   File #:  1-39780

Previous ‘10-Q’:  ‘10-Q’ on 5/12/22 for 3/31/22   ·   Next:  ‘10-Q’ on 11/10/22 for 9/30/22   ·   Latest:  ‘10-Q’ on 11/14/23 for 9/30/23   ·   7 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/15/22  Cyclo Therapeutics, Inc.          10-Q        6/30/22   44:3.2M                                   RDG Filings/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    580K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     19K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     19K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     14K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     14K 
11: R1          Document And Entity Information                     HTML     71K 
12: R2          Consolidated Balance Sheets (Current Period         HTML     97K 
                Unaudited)                                                       
13: R3          Consolidated Balance Sheets (Current Period         HTML     30K 
                Unaudited) (Parentheticals)                                      
14: R4          Consolidated Statements of Operations (Unaudited)   HTML     88K 
15: R5          Consolidated Statements of Stockholders' Equity     HTML     70K 
                (Unaudited)                                                      
16: R6          Consolidated Statements of Cash Flows (Unaudited)   HTML     87K 
17: R7          Note 1 - Summary of Significant Accounting          HTML     56K 
                Policies                                                         
18: R8          Note 2 - Revenues                                   HTML     35K 
19: R9          Note 3 - Major Customers and Suppliers              HTML     18K 
20: R10         Note 4 - Mortgage Note Receivable                   HTML     17K 
21: R11         Note 5 - Note Payable                               HTML     21K 
22: R12         Note 6 - Equity Transactions                        HTML     27K 
23: R13         Note 7 - Income Taxes                               HTML     19K 
24: R14         Note 8 - Equity Incentive Plan                      HTML     22K 
25: R15         Note 9 - Net Loss Per Share                         HTML     37K 
26: R16         Note 10 - Subsequent Events                         HTML     17K 
27: R17         Significant Accounting Policies (Policies)          HTML     99K 
28: R18         Note 2 - Revenues (Tables)                          HTML     29K 
29: R19         Note 9 - Net Loss Per Share (Tables)                HTML     37K 
30: R20         Note 1 - Summary of Significant Accounting          HTML     60K 
                Policies (Details Textual)                                       
31: R21         Note 2 - Revenues (Details Textual)                 HTML     23K 
32: R22         Note 2 - Revenues - Revenues by Product (Details)   HTML     27K 
33: R23         Note 3 - Major Customers and Suppliers (Details     HTML     28K 
                Textual)                                                         
34: R24         Note 4 - Mortgage Note Receivable (Details          HTML     21K 
                Textual)                                                         
35: R25         Note 5 - Note Payable (Details Textual)             HTML     15K 
36: R26         Note 6 - Equity Transactions (Details Textual)      HTML     94K 
37: R27         Note 8 - Equity Incentive Plan (Details Textual)    HTML     62K 
38: R28         Note 9 - Net Loss Per Share - Earnings Per Share    HTML     34K 
                (Details)                                                        
39: R29         Note 9 - Net Loss Per Share - Antidilutive          HTML     19K 
                Securities Weighted Average Shares Outstanding                   
                (Details)                                                        
42: XML         IDEA XML File -- Filing Summary                      XML     74K 
40: XML         XBRL Instance -- ctdh20220630_10q_htm                XML    703K 
41: EXCEL       IDEA Workbook of Financial Reports                  XLSX     69K 
 7: EX-101.CAL  XBRL Calculations -- ctdh-20220630_cal               XML     80K 
 8: EX-101.DEF  XBRL Definitions -- ctdh-20220630_def                XML    664K 
 9: EX-101.LAB  XBRL Labels -- ctdh-20220630_lab                     XML    542K 
10: EX-101.PRE  XBRL Presentations -- ctdh-20220630_pre              XML    672K 
 6: EX-101.SCH  XBRL Schema -- ctdh-20220630                         XSD     94K 
43: JSON        XBRL Instance as JSON Data -- MetaLinks              221±   347K 
44: ZIP         XBRL Zipped Folder -- 0001437749-22-020532-xbrl      Zip    140K 




        
Filing Submission 0001437749-22-020532 – SGML Text

Original SGML Text submitted by:  RDG Filings/FA  (as Filing Agent) 

To view the SGML, please refresh
Refresh emoji
this page.


Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 6:07:39.2pm ET